Decentralized clinical trial specialist Curebase has secured $40 million in Series B funding thanks to the support of Industry Ventures and others.
Other investors contributing to the funding round include Acrew Capital, World Innovation Lab, Positive Sum, Gilead Sciences and existing investors GGV Capital, Bold Capital and Xfund.
The San Francisco–based company has worked to popularize the concept of “BYOP” — “bring your own physician” to make clinical trials available to patients regardless of location.
“Traditional clinical trials at big hospitals tend to be slower, more expensive, less diverse,” said Tom Lemberg, CEO of Curebase. “Our objective as a company is to bring the trial to the patient both at home and with their own physician.”
Tom Lemberg
Curebase says its decentralized approach can accelerate recruiting, facilitate clinical t…